Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines.
about
Cationic liposome-hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigensStructure and Immunogenicity of a Peptide Vaccine, Including the Complete HIV-1 gp41 2F5 EpitopeFacial recognition of heroin vaccine opiates: type 1 cross-reactivities of antibodies induced by hydrolytically stable haptenic surrogates of heroin, 6-acetylmorphine, and morphineLiposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs.Liposomes as vaccine delivery systems: a review of the recent advances.Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides.Adjuvants for vaccines to drugs of abuse and addiction.The Atomic Structure of the HIV-1 gp41 Transmembrane Domain and Its Connection to the Immunogenic Membrane-proximal External RegionVaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondiiEnhancing nicotine vaccine immunogenicity with liposomes.Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID "Meet the Experts" 2015 Workshop Summary.Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles.Multifunctional particle-constituted microneedle arrays as cutaneous or mucosal vaccine adjuvant-delivery systemsAdjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.Liposomal adjuvants for human vaccines.Liposomes as nanocarriers for anti-HIV therapy.Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model.Protein nanovaccine confers robust immunity against Toxoplasma.Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant.A Stable Heroin Analogue That Can Serve as a Vaccine Hapten to Induce Antibodies That Block the Effects of Heroin and Its Metabolites in Rodents and That Cross-React Immunologically with Related Drugs of Abuse.Encapsulation of Hydrophilic and Hydrophobic Peptides into Hollow Mesoporous Silica Nanoparticles for Enhancement of Antitumor Immune Response.Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex.The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases.Preparation of Multifunctional Liposomes as a Stable Vaccine Delivery-Adjuvant System by Procedure of Emulsification-Lyophilization.Diverse pro-inflammatory endotoxin recognition systems of mammalian innate immunity.
P2860
Q27310007-BF3F7CDC-1D3E-47D4-9D6E-BD1509FBDC93Q27681352-61E5E699-BED9-4305-A4EA-570A0951ADD1Q33874955-67CC3C2C-B507-432E-A4E9-D846A9E7CBC6Q33994987-A9D0B3DE-7DC7-466C-9659-B812358514C2Q34418761-F44C8DBE-7EFD-412A-A3D4-DAD92786DEB2Q35034311-24872DEB-7E54-4EC7-B5B8-8CD9CB47A8ECQ35493923-8C580F85-6DFC-4E2A-A663-907508B4ECD2Q35860914-6D324969-F9C5-4822-9501-91347247749DQ36240866-6FC9C4DD-DA61-4E24-AC15-26D0C7EC7B85Q36569318-513638E5-C5A7-4F90-9C10-A833B6CC90EFQ36601983-D6508018-E9C7-4990-80D6-9C941810E280Q36951570-016EAA1E-099B-4C27-8C96-61A2968E5021Q37184111-261F428B-07F5-47C3-A632-FD11545E367BQ37197084-DBD36F13-CB5B-4DE2-9C74-BF9B8B7C14DAQ37410524-6E84B588-3E1F-448D-97DC-09BE417CA52CQ38729260-3E589436-B01C-468D-B290-7345A3F06499Q41195459-82BD4A05-0FCF-4EDA-AC64-155445E011E3Q42680550-F23AAF28-6630-4691-8D18-D81DED4605FDQ47102683-88FF0358-4230-4D82-AF82-E8152B1FFDB9Q47105347-3A9B7CF4-CA0F-4352-A240-1527B4CFC430Q47253367-821A4EEE-05AF-4A2A-8182-3D1ED45738BBQ47730028-D2F1CC68-97E0-418C-B1B8-C00A41D5C5BBQ50060583-52E96590-2CC8-42E3-9D12-17C4B2AF2AA2Q50124824-AFFBB950-A10C-4187-B4B0-E3CD19D13C71Q51372198-FA3BC015-2AC6-46D0-BAEA-F433AD6E063EQ55396774-4BC95E3C-148D-4C28-9C22-3E71EE2E2E1A
P2860
Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Liposomes containing lipid A: ...... system for synthetic vaccines.
@en
type
label
Liposomes containing lipid A: ...... system for synthetic vaccines.
@en
prefLabel
Liposomes containing lipid A: ...... system for synthetic vaccines.
@en
P2093
P2860
P356
P1476
Liposomes containing lipid A: ...... system for synthetic vaccines.
@en
P2093
Alexander V Mayorov
Carl R Alving
Mangala Rao
Nicholas J Steers
P2860
P304
P356
10.1586/ERV.12.35
P577
2012-06-01T00:00:00Z